Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma

Part of paid clinical trials in Portland, Oregon.

Sponsor
Providence Health & Services
Study ID
NCT05308901
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Melanoma, Uveal

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    200 mg IV every 3 weeks for a maximum of 2 years.
  • Lenvatinib — DRUG
    20 mg daily for a maximum of 2 years.

Study Details

The purpose of this study is to evaluate the efficacy of lenvatinib and pembrolizumab to treat metastatic uveal melanoma.

Key Dates

Start date
Aug 2, 2022
Status verified
Jul 2025
Primary completion
Dec 3, 2024
Completion
Jun 30, 2027

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab + Lenvatinib
    Lenvatinib 20 mg daily plus pembrolizumab 200 mg IV every 3 weeks.

Primary Outcome Measure

Evaluate the Effect of Lenvatinib Plus Pembrolizumab on Progression Free Survival [ Time Frame: An average of 6 months and 7 days from the time of enrollment. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Providence Portland Medical CenterPortlandOregon97213-

Related coverage on Hipa.ai

Find similar trials in Portland, OR

By research site
Providence Portland Medical Center· Portland, OR